SCHEMBL1679794

SCHEMBL1679794

CC(C)(C)c1nc2c3cc[nH]c(=O)c3c3cc(F)ccc3c2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 17/20 1.00
CHEK1 O14757 4/20 1.00
JAK3 P52333 3/20 1.00
JAK1 P23458 2/20 1.00
TYK2 P29597 2/20 1.00
IKBKB O14920 1/20 1.00
MAPK13 O15264 1/20 1.00
DAPK3 O43293 1/20 1.00
PRKD3 O94806 1/20 1.00
FYN P06241 1/20 1.00
RET P07949 1/20 1.00
HCK P08631 1/20 1.00
PDGFRB P09619 1/20 1.00
PIM1 P11309 1/20 1.00
FGFR1 P11362 1/20 1.00
PDGFRA P16234 1/20 1.00
PRKCA P17252 1/20 1.00
PRKACA P17612 1/20 1.00
FLT1 P17948 1/20 1.00
FGFR2 P21802 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29521847 0.95 JAK2 (0.91) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL904545 0.95 JAK2 (0.91) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL13741485 0.83 JAK2 (0.71) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL5759753 0.81 JAK2 (0.68) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL3311115 0.81 JAK2 (0.67) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL5761824 0.80 JAK2 (0.66) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL5759495 0.79 JAK2 (0.65) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2304822 0.78 JAK2 (0.64) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL4099738 0.77 JAK2 (0.63) JAK2CHEK1JAK3JAK1TYK2
SCHEMBL2305886 0.77 JAK2 (0.62) JAK2CHEK1JAK3JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115207999-B Multi-fast charge protocol control circuit, control method, related chip and electronic equipment Shenzhen yingjixin Technology Co.,Ltd. (CN) 2026-05-26 CN claimed
EP-4697578-A1 SINGLE-INDUCTOR MULTIPLE-OUTPUT VOLTAGE CONVERTER, POWER SUPPLY CHIP, AND ELECTRONIC DEVICE Telink Semiconductor (Shanghai) Co., Ltd. (CN) 2026-02-18 EP claimed
CN-118349076-A Rapid MPPT method based on power detection and quantification for radio frequency energy acquisition 西安电子科技大学重庆集成电路创新研究院 2024-07-16 CN claimed
CN-117767790-A Synchronous management circuit for piezoelectric vibration energy collection and power supply 西安电子科技大学 2024-03-26 CN claimed
CN-116829707-A Method for improving fixed point integration frequency 孟山都技术公司 2023-09-29 CN claimed
CN-116301140-A Reference current source 中国科学技术大学 2023-06-23 CN claimed
CN-115207999-A Multi-quick-charging-protocol control circuit, control method, related chip and electronic equipment 深圳英集芯科技股份有限公司 2022-10-18 CN claimed
WO-2022214083-A1 MULTI-FAST CHARGING PROTOCOL CONTROL CIRCUIT, CONTROL METHOD, CHIP, AND ELECTRONIC DEVICE 深圳英集芯科技股份有限公司 2022-10-13 WO claimed
US-20220184217-A1 HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF Fusion Pharmaceuticals Inc. (CA) 2022-06-16 US claimed
EP-3946320-A1 HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF Tarveda Therapeutics, Inc. (US) 2022-02-09 EP claimed
CN-115207999-B Multi-fast charge protocol control circuit, control method, related chip and electronic equipment Shenzhen yingjixin Technology Co.,Ltd. (CN) 2026-05-26 CN disclosed
US-12627224-B2 Resonant power convertor and control method thereof RICHTEK TECHNOLOGY CORPORATION (TW) 2026-05-12 US disclosed
US-20260121528-A1 RESONANT POWER CONVERSION CIRCUIT AND DRIVING METHOD THEREOF FOR ELIMINATING AUDIO NOISE RICHTEK TECHNOLOGY CORP (TW) 2026-04-30 US disclosed
US-12610793-B2 Method of manufacturing memory device MACRONIX INTERNATIONAL CO., LTD. (TW) 2026-04-21 US disclosed
US-12590963-B2 Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) 2026-03-31 US disclosed
US-20180214449-A1 CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS UBRX, INC. 2018-08-02 US disclosed
US-7919261-B2 Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers MERCK SHARP & DOHME CORP. (US) 2011-04-05 US disclosed
US-20090304594-A1 Methods for Predicting Treatment Response Based On the Expression Profiles of Protein and Transcription Biomarkers MERCK SHARP & DOHME CORP. 2009-12-10 US disclosed
US-7593820-B2 Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof CYTOPIA RESEARCH PTY LTD (AU) 2009-09-22 US disclosed
US-7593820-B2 Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof CYTOPIA RESEARCH PTY LTD (AU) 2009-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260121528-A1 RESONANT POWER CONVERSION CIRCUIT AND DRIVING METHOD THEREOF FOR ELIMINATING AUDIO NOISE FCER2, TMCO1, CRY1 JAK2 3040/4885CHEK1 1634/4885JAK3 1582/4885
US-20220184217-A1 HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF HSP90AB1, HSP90B1, HSP90AA1 JAK2 3694/4885CHEK1 1882/4885JAK3 4711/4885
US-12610793-B2 Method of manufacturing memory device PIEZO1, MEF2D, SMCHD1 JAK2 3272/4885CHEK1 453/4885JAK3 772/4885
US-12627224-B2 Resonant power convertor and control method thereof RCOR1, RCOR3, TRRAP JAK2 865/4885CHEK1 1231/4885JAK3 724/4885
US-20180214449-A1 CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885CHEK1 156/4885JAK3 3/4885
US-12590963-B2 Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects TPM4, TPM3, TAGLN2 JAK2 3979/4885CHEK1 1136/4885JAK3 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.